Humacyte Inc (HUMA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Humacyte Inc (HUMA) has a cash flow conversion efficiency ratio of 5.031x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-23.90 Million) by net assets ($-4.75 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Humacyte Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Humacyte Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Humacyte Inc for a breakdown of total debt and financial obligations.
Humacyte Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Humacyte Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SAB Biotherapeutics Inc
NASDAQ:SABS
|
-0.079x |
|
Socovesa
SN:SOCOVESA
|
-0.126x |
|
Teladan Setia Group Bhd
KLSE:0230
|
0.033x |
|
Ilex Medical
TA:ILX
|
0.068x |
|
centrotherm international AG
F:CTNK
|
0.077x |
|
Vieworks Co. Ltd
KQ:100120
|
0.076x |
|
PHX Minerals Inc
NYSE:PHX
|
0.034x |
|
Rent the Runway Inc
NASDAQ:RENT
|
0.040x |
Annual Cash Flow Conversion Efficiency for Humacyte Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Humacyte Inc from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see HUMA stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-52.67 Million | $-98.12 Million | 1.863x | +134.43% |
| 2023-12-31 | $13.55 Million | $-73.31 Million | -5.412x | -789.60% |
| 2022-12-31 | $116.93 Million | $-71.13 Million | -0.608x | +8.46% |
| 2021-12-31 | $122.17 Million | $-81.19 Million | -0.665x | +15.48% |
| 2020-12-31 | $70.67 Million | $-55.57 Million | -0.786x | -44.80% |
| 2019-12-31 | $132.20 Million | $-71.79 Million | -0.543x | -- |
About Humacyte Inc
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to b… Read more